pharma · Cystic Fibrosis · Hepatitis C
Vertex Pharmaceuticals (Australia)
Vertex Pharmaceuticals (Australia) Pty.
Vertex Pharmaceuticals (Australia) is a pharma organization headquartered in Boston, USA. Primary therapeutic focus areas include Cystic Fibrosis, Hepatitis C, Pain, Chronic Hepatitis C, Acute Pain. NovaPharmaNews links
Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, MA 02210, US HQ
1989 Founded
6,304 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- Vertex Pharmaceuticals Inc., 50 Northern Avenue, Boston, MA 02210, US
- Founded
- 1989
- Employees
- 6,304
- Programs
- 159
- Drugs
- 64
- Patents
- 991
lumacaftor 200 mg q12h + ivacaftor 250 mg q12h
Phase 1 · small molecule · Hepatic Impairment
lumacaftor 200 mg q12h + ivacaftor 250 mg q12h for Hepatic Impairment is a Phase 1 program (small_molecule) at Vertex Pharmaceuticals (Australia) Pty. with 1 ClinicalTrials.gov record(s).
Internal code VX13-809-010
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Vertex Pharmaceuticals (Australia) Pty.
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- Hepatic Impairment
- Status
- completed
- Trials
- 1